Lumateperone

Indications

• Schizophrenia in adults, at a single fixed dose that requires no titration and no dose finding.
• Depressive episodes associated with bipolar I or bipolar II disorder in adults, as monotherapy and as adjunct to lithium or valproate.
• Adjunctive therapy with antidepressants for major depressive disorder in adults, an indication added to the US label in 2025.
• Bipolar II depression coverage is notable, since most approved agents in this space are limited to bipolar I disorder.
• Off-label appeal is greatest in patients where weight gain, akathisia, or prolactin elevation ended prior antipsychotic trials.

Mechanism of action

• Very potent 5-HT2A antagonism with roughly 60-fold higher affinity than for D2, which is the highest ratio among available agents.
• Acts as a presynaptic dopamine D2 partial agonist and a postsynaptic D2 antagonist, giving modulation rather than pure blockade.
• Indirectly modulates glutamate through D1-dependent enhancement of NMDA and AMPA currents in prefrontal cortex.
• Moderate inhibition of the serotonin transporter contributes to antidepressant activity in bipolar and unipolar depression.
• Negligible histamine, muscarinic, and alpha-1 affinity explains minimal weight gain, low anticholinergic load, and little orthostasis.

Pharmacokinetics

• Absorbed with or without food, though a high-fat meal lowers peak concentration and delays absorption without changing overall exposure.
• Cleared by multiple UGT isoforms, aldoketoreductase, and CYP3A4, producing more than fifty metabolites of limited clinical importance.
• Terminal half-life is about 18 hours, supporting once-daily dosing with steady state reached in roughly 5 days.
• Exposure roughly doubles with moderate to severe hepatic impairment, which is why the dose drops to 21 mg in Child-Pugh class B or C.
• Strong CYP3A4 inhibition raises exposure severalfold, so the dose falls to 10.5 mg rather than being simply monitored.

Dosing

• The recommended dose is 42 mg once daily for every approved indication, with no titration and no dose adjustment for response.
• Capsules are available as 42 mg, 21 mg, and 10.5 mg, with the smaller strengths existing purely for interaction and hepatic adjustments.
• Reduce to 21 mg once daily with a moderate CYP3A4 inhibitor and to 10.5 mg once daily with a strong CYP3A4 inhibitor.
• Reduce to 21 mg once daily in moderate or severe hepatic impairment; mild impairment needs no change.
• Avoid concomitant CYP3A4 inducers, since exposure falls substantially and no compensating dose increase is defined.
• Taper is not formally required, but gradual discontinuation is prudent in patients with a history of rapid relapse.

Adverse effects

• Somnolence and sedation are the most common effects, reported by roughly 24 percent in trials and usually manageable with evening dosing.
• Dry mouth, nausea, dizziness, and elevations in creatine phosphokinase or transaminases are the other frequent findings.
• Weight change is close to placebo in short-term trials, one of the strongest arguments for the drug in metabolically vulnerable patients.
• Extrapyramidal symptoms, akathisia, and prolactin elevation are all low, which distinguishes it from risperidone and aripiprazole.
• Labeled risks include neuroleptic malignant syndrome, tardive dyskinesia, orthostatic hypotension, seizures, and leukopenia or neutropenia.
• Cerebrovascular events and increased mortality are the specific concerns in elderly patients with dementia-related psychosis.

Monitoring

• Weight, BMI, blood pressure, fasting glucose or A1c, and lipids at baseline, at 12 weeks, and annually, despite the favorable profile.
• Complete blood count in patients with pre-existing low white cell count or a history of leukopenia, with discontinuation if ANC falls below 1000/uL.
• Hepatic panel at baseline to establish whether the reduced 21 mg dose applies, and again if transaminases rise on treatment.
• AIMS examination at baseline and every 6-12 months, since low short-term motor risk does not eliminate tardive dyskinesia over years.
• Review the medication list for CYP3A4 inhibitors and inducers at every visit, since dosing hinges entirely on that pathway.

Interactions

• Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, and ritonavir require reducing the dose to 10.5 mg daily.
• Moderate CYP3A4 inhibitors including diltiazem, verapamil, erythromycin, and fluconazole require reducing the dose to 21 mg daily.
• CYP3A4 inducers such as rifampin, carbamazepine, and St. John's wort should be avoided because exposure falls markedly.
• Additive sedation with opioids, benzodiazepines, and alcohol, which matters given the drug's leading adverse effect is somnolence.
• Contraindicated in patients with a history of hypersensitivity reaction to lumateperone, including rash, pruritus, or urticaria.

Special populations

• Human pregnancy data are limited; third-trimester exposure carries the class risk of neonatal extrapyramidal and withdrawal symptoms.
• Lactation data are absent, so monitor breastfed infants for sedation and feeding difficulty or select a better-characterized agent.
• Safety and effectiveness have not been established in pediatric patients, so use is restricted to adults.
• In older adults the low anticholinergic and orthostatic burden is attractive, but the dementia mortality warning still applies.
• Reduce to 21 mg daily in moderate or severe hepatic impairment; no renal dose adjustment has been specified.

Clinical pearls

• One dose for every indication: 42 mg daily, with no titration and nothing to optimize.
• The 21 mg and 10.5 mg capsules exist only for hepatic impairment and CYP3A4 inhibitors.
• Among the few options approved for bipolar II depression, not just bipolar I.